ATENT COOPERATION TRL .TY

	From the INTERNATIONAL BUREAU
PCT	To:
NOTIFICATION OF ELECTION (PCT Rule 61.2)	Assistant Commissioner for Patents United States Patent and Trademark Office Box PCT Washington, D.C.20231 ÉTATS-UNIS D'AMÉRIQUE
late of mailing (day/month/year) 13 December 1999 (13.12.99)	in its capacity as elected Office
nternational application No. PCT/GB99/01387	Applicant's or agent's file reference IPD/P1203/WOD
nternational filing date (day/month/year) 05 May 1999 (05.05.99)	Priority date (day/month/year) 29 May 1998 (29.05.98)
Applicant BENNETT, Alice, Marie	
in the demand filed with the International Prelimage 23 Nover in a notice effecting later election filed with the	mber 1999 (23.11.95)
2. The election X was was was not was not made before the expiration of 19 months from the Rule 32.2(b).	priority date or, where Rule 32 applies, within the time limit under
	Authorized officer
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Juan Cruz
240 14 25	Telephone No.: (41-22) 338.83.38



PATENT COOPERATION TREATY

PCT ...

REC'D 0 7 NOV 2000

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant	s or age	ent's file reference		See Notification of Transmittal of International
IPD/P1	203/W	OD	FOR FURTHER ACTION	Preliminary Examination Report (Form PCT/IPEA/416)
Internatio	nal appi	ication No.	International filing date (day/mon	
PCT/GI	399/01	387	05/05/1999	29/05/1998 RECENTED
Internatio C12N1		ent Classification (IPC) or na	tional classification and IPC	29/05/1998 RECEIVED 0CT 2 6 2001
Applicant				TECH CENTER 1600/2900
		TARY OF STATE FOR	DEFENCE et al.	
		ational preliminary exam smitted to the applicant a		ed by this International Preliminary Examining Authority
2. This	REPO	ORT consists of a total of	7 sheets, including this cover	sheet.
	been a	amended and are the bas	d by ANNEXES, i.e. sheets of sis for this report and/or sheets 07 of the Administrative Instruc	the description, claims and/or drawings which have containing rectifications made before this Authority ctions under the PCT).
The	se ann	exes consist of a total of	sheets.	
3. This	report	t contains indications rela	ating to the following items:	
	ı ⊠	Basis of the report		
ı	ı 🗆	•		
11	! ⊠	Non-establishment of o	pinion with regard to novelty, i	nventive step and industrial applicability
IV.	<i>,</i> 0	Lack of unity of invention		
\	<i>i</i> 🛭		nder Article 35(2) with regard to ons suporting such statement	o novelty, inventive step or industrial applicability;
l v	ı 🛭	Certain documents cite	ed	
VI	ı - 🗆	Certain defects in the in	nternational application	
VII	⊠	Certain observations o	n the international application	
Date of s	ubmissi	on of the demand	Date of	of completion of this report
23/11/1	999		02.11	.2000
,	гу ехал	g address of the international	al Autho	rized officer
<u> </u>	D-8	opean Patent Office 0298 Munich . +49 89 2399 - 0 Tx: 52365		nessier, T
		: +49 89 2399 - 4465	· ·	hone No. +49 89 2399 8687

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB99/01387

I.	Basis	of the	report
••	2431	, 41 1114	, . .

1.	resp	onse to an invitation	rawn on the basis of (sub on under Article 14 are rei o not contain amendment	stitute sheets which have been furnished to the receiving Office in ferred to in this report as "originally filed" and are not annexed to s.):
	Des	cription, pages:		
	1-13	:	as originally filed	
	Clai	ms, No.:		
	1-18	3	as originally filed	RECEIVED
				OCT 2 6 2001
	Dra	wings, No.:		
	1a,2	2-4	as originally filed	TECH CENTER 1600/2900
2.	The	amendments have	e resulted in the cancellat	ion of:
		the description,	pages:	
		the claims,	Nos.:	
		the drawings,	sheets:	•
3.		This report has be considered to go	een established as if (som beyond the disclosure as	ne of) the amendments had not been made, since they have been filed (Rule 70.2(c)):
4.	Ado	litional observation	ns, if necessary:	
			•	
Ш	. N oı	n-establishment c	of opinion with regard to	novelty, inventive step and industrial applicability
TI or	re qu	estions whether the industrially applic	ne claimed invention appe cable have not been exam	ars to be novel, to involve an inventive step (to be non-obvious), nined in respect of:
		the entire interna	tional application.	
	Ø	claims Nos. 16 a	nd 17.	
b	ecau	se:		

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB99/01387

	ឪ		ne said international application, or the said claims Nos. 16 and 17 (with respect to industrial applicability) elate to the following subject matter which does not require an international preliminary examination specify):				
		see separate sheet					
	_	the description, claims o that no meaningful opini			cate particular elements below) or said ned (specify):	claims Nos. are so unclear	
		the claims, or said claim could be formed.	s Nos.	are so in	adequately supported by the description	on that no meaningful opinion	
		no international search r	report h	as been e	established for the said claims Nos		
٧.				• •	ith regard to novelty, inventive step upporting such statement	or industrial	
1.	Stat	ement					
	Nov	relty (N)	Yes: No:	Claims Claims	1-18		
	Inve	entive step (IS)	Yes: No:		1-13 and 15-18 (partly) 14 and 15-18 (partly)	RECEIVED	
	Indu	ustrial applicability (IA)	Yes: No:	Claims Claims	1-15 and 18	OCT 2 6 2001 TECH CENTER 1600/2900	
2.	Cita	tions and explanations				72011 OLIVIER 1600/2900	
	see	separate sheet					
VI.	. Cer	tain documents cited					
1.	Cert	tain published documents	s (Rule	70.10)		÷	
	and	/ or					
2.	Non	-written disclosures (Rule	e 70.9)				
	see	separate sheet					

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB99/01387

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Comments with respect to item I

Sequence listing pages 1-2 filed with the letter sent in reply to the invitation to furnish nucleotide sequence listing [Form ISA225] do not form part of the application (Rule 13^{ter}.1(f) PCT).

Comments with respect to item III

Claims 16 and 17 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

Comments with respect to item V

a) Documents cited

Reference is made to the following documents:

- * D1: Viral Immunology, 11(3), 1998, 109-117
- D2: The Journal of General Virology, 69, 1988, 3005-13
- * D3: Journal of Molecular Biology, 210(4), 1989, 749-69

The inventor appears to have contributed to document D1 which can be regarded as a non-patent literature counterpart of the present application.

b) Novelty (Article 33(2) PCT)

The various aspects of the invention appear not to be disclosed in any of the documents belonging to the relevant state of the art, and, therefore can be acknowledged as new.

c) Inventive step (Article 33(3) PCT)

(i) Furthermore, it is considered that none of the afore-mentioned

documents would have suggested to a person skilled in the art at the priority date that the presence of a lysine residue at position 7 in the E2 protein of VEE would be capable of enhancing immunogenicity of a vaccine as defined in claim 1 compared to existing live attenuated vaccines such as the vaccine referred to as TC-83.

- Therefore, it can be acknowlegded that the subject-matter of claims (ii) 1- 13 involves an inventive step, the same conclusion applying de facto to those embodiments of the inventions of claims 15-18 which are defined using a back-reference to any one of claims 1-13.
- From document D2 it can be derived that the 7.5K vaccinia promoter is (iii) appropriate to correctly express VEE genes inserted into a vaccinia virus. Furthermore, document D3 teaches that synthetic promoters efficient at increasing protein expression can be constructed which correspond to the 7.5K vaccinia promoter with mutations within the critical region AAAAgTaGAAAataTA. Therefore, it is considered that a person skilled in the art would have regarded it as obvious to combine the teachings of document D2 and D3 and would have been prompted to prepare a vaccinia virus vector encoding an attenuated form of the VEE virus capable of producing a protective immune response, the corresponding DNA sequence being placed under expression control of a such a synthetic 7.5K vaccinia promoter with a view to increasing the amount of VEE proteins produced.
- (iv) Consequently, it is considered that the subject-matter of the broadly formulated claim 14 does not involve an inventive step, the same conclusion applying de facto to those embodiments of the inventions of claims 15-18 which are defined using a back-reference to claim 14.
- Industrial applicability (Article 33(4) PCT) d)
 - It is considered that the subject-matter of claims 1-15 and 18 is (i) susceptible of industrial applicability.

(ii) For the assessment of claims 16 and 17 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

4. Comments with respect to item VI

Should the invention appear not to be entitled to the claimed priority date, document D1 should be taken into consideration when assessing whether the various aspects of the invention are new and involve an inventive step.

5. Comments with respect to item VIII

Claim 5 is objected to under Article 6 PCT for the following reasons:

- (i) "BCG" is the abbreviation commonly used to designate the <u>Bacillus</u>

 <u>Calmette-Guérin</u> which is a not a virus but a <u>bacterium</u>; and
- (ii) "BCC" would appear not to be an abbreviation commonly used in the field of virology. Therefore, it is not clear which virus is meant under the said abbreviation.





Application No:

GB 9811433.3

Examiner:

Colin Sherrington

Claims searched:

1 to 15, 18

Date of search:

4 August 1998

Patents Act 1977 Search Report under Section 17

Databases searched:

UK Patent Office collections, including GB, EP, WO & US patent specifications, in:

UK Cl (Ed.P): C3H(HB7M,HB7V)

Int Cl (Ed.6): A61K 39/12; C07K 14/18; C12N 15/86

Other: ONLINE: WPI, CLAIMS, DIALOG/BIOTECH

Documents considered to be relevant:

Category	Identity of docum	ment and relevant passage	Relevant to claims	
Α	US 5185440	(NORTH CAROLINA STATE UNIVERSITY) - whole document	1, 15	PCT
Α	US 5505947	(THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL) -whole document	1, 15	-
A	"Recombinant V	8,69,3005-3013 -Richard M.Kinney et al. accinia/Venezuelan Equine Encephalitis (VEE) Virus Structural Proteins"	14, 15	PCT
Α	Restrictions in th	06,994-1006 -Franziska B.Grieder et al. "Specific the Progression of Venezuelan Equine Encephalitis Virus-Resulting from Single Amino Acid Changes in the	1, 15	

^	Document	indicating	lack	or nove	ity or	. IUA	entive	e step	
v	D								

Y Document indicating tack of inventive step if combined with one or more other documents of same category.

Member of the same patent family

- A Document indicating technological background and/or state of the art.
- P Document published on or after the declared priority date but before the filing date of this invention.
- E Patent document published on or after, but with priority date earlier than, the filing date of this application.

W.



PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification	of Transmittal of International Search Report
IPD/P1203/WOD	ACTION See Notification (Form PCT/ISA/	220) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/GB 99/01387	05/05/1999	29/05/1998
Applicant	00,00,1777	27/03/1770
THE SECRETARY OF STATE FO This International Search Report has bee according to Article 18. A copy is being trace. This International Search Report consists. X It is also accompanied by 1. Basis of the report a. With regard to the language, the	en prepared by this International Searching Aut ansmitted to the International Bureau.	report.
	vas carried out on the basis of a translation of t	he international application furnished to this
was carned out on the basis of the contained in the internation filed together with the internation furnished subsequently to the statement that the subsequently to the statement that the subsequently to the statement that the informational application at the statement that the informationed	e sequence listing ; conal application in written form. conal application in computer readable form conthis Authority in written form. conthis Authority in computer readble form. conthis Authority in computer readable form is continuous filed has been furnished. computer readable form is continuous filed has been furnished.	
	Ibmitted by the applicant. Thed by this Authority to read as follows: NEQUINE ENCEPHALITIS VIRUS	VACCINE
5. With regard to the abstract, The text is approved as su the text has been establish within one month from the	bmitted by the applicant. hed, according to Rule 38.2(b), by this Authorit date of mailing of this international search rep	y as it appears in Box III. The applicant may, ort, submit comments to this Authority.
6. The figure of the drawings to be publi as suggested by the applicant faile because this figure better	cant.	None of the figures.

INTERNATIONAL SEARCH REPORT

International application No. PCT/GB 99/01387

Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This Inte	rnational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 16-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the vaccine.
	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	rnational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/63 A61K39/12 A61K39/295

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) I PC $\,6\,$ A61K $\,$ C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KINNEY R M ET AL: "Recombinant vaccinia/Venezuelan equine encephalitis (VEE) virus expresses VEE structural proteins." JOURNAL OF GENERAL VIROLOGY, (1988 DEC) 69 (PT 12) 3005-13., XP002118353 cited in the application page 3005 -page 3006 page 3007; figure 1	14-18
(DAVISON, ANDREW J. ET AL: "Structure of vaccinia virus early promoters" J. MOL. BIOL. (1989), 210(4), 749-69, XP002118354 page 749 page 767, left-hand column -page 769, right-hand column	14-18

	-/
X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family
Date of the actual completion of the international search 11 October 1999	Date of mailing of the international search report 2 2. 10, 99
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Mennessier, T

Form PCT/ISA/210 (second sheet) (July 1992)

1

Category * Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	The valit to claim No.
KINNEY R M ET AL: "The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83." VIROLOGY, (1989 MAY) 170 (1) 19-30., XP002117670 the whole document	1-18
HUNT A R ET AL: "Localization of a protective epitope on a Venezuelan equine encephalomyelitis (VEE) virus peptide that protects mice from both epizootic and enzootic VEE virus challenge and is immunogenic in horses." VACCINE, (1995 FEB) 13 (3) 281-8., XP004057668 cited in the application the whole document	1-18
AGAPOV E V ET AL: "Localization of four antigenic sites involved in Venezuelan equine encephalomyelitis virus protection." ARCHIVES OF VIROLOGY, (1994) 139 (1-2) 173-81., XP002117671 the whole document	1-18
US 5 185 440 A (JOHNSTON ROBERT E ET AL) 9 February 1993 (1993-02-09) the whole document	1-18
BENNETT A M ET AL: "Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus." VIRAL IMMUNOLOGY, (1998) 11 (3) 109-17., XP002117672 the whole document	1-18

IN NATIONAL SEARCH REPORT

PCT/GB 99/01387

Publication Patent family Patent document Publication member(s) date cited in search report date US 5185440 09-02-1993 NONE